We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

57 hedge funds and large institutions have $313M invested in Arcus Biosciences in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

14% more capital invested

Capital invested by funds: $274M → $313M (+$38.7M)

0.09% more ownership

Funds ownership: 50.38% → 50.47% (+0.09%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less funds holding

Funds holding: 64 → 57 (-7)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
57
Holders Change
-7
Holders Change %
-10.94%
% of All Funds
1.3%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
4
Increased
27
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$2.75M
2
Millennium Management
Millennium Management
New York
+$1.45M
3
BlackRock
BlackRock
New York
+$1.28M
4
BI
BVF Inc
California
+$1.26M
5
PIM
Platinum Investment Management
Australia
+$548K

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.26M
2
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$2.25M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.07M
4
LCM
Laurion Capital Management
New York
-$734K
5
PHS
PFM Health Sciences
California
-$567K
Name Holding Trade Value Shares
Change 		Change in
Stake
IUHSA
51
Itau Unibanco Holding S.A.
Brazil
$13K -$434 -34 -3%
LTFS
52
Ladenburg Thalmann Financial Services
Florida
$11K – – –
AIP
53
Ameritas Investment Partners
Nebraska
$6K – – –
BNP Paribas Financial Markets
54
BNP Paribas Financial Markets
France
$2.36K -$13 -1 -0.6%
TRCT
55
Tower Research Capital (TRC)
New York
$1K -$27.5K -2,160 -97%
CPIG
56
Chicago Partners Investment Group
Illinois
$1K – – –
Bank of Montreal
57
Bank of Montreal
Ontario, Canada
$1K +$344 +27 +73%
Alyeska Investment Group
58
Alyeska Investment Group
Illinois
– -$1.07M -87,808 Closed
LCM
59
Laurion Capital Management
New York
– -$734K -60,000 Closed
HH
60
Hilltop Holdings
Texas
– -$136K -11,075 Closed
CSS
61
Cubist Systematic Strategies
Connecticut
– -$123K -10,009 Closed
WMSA
62
Weiss Multi-Strategy Advisers
New York
– -$122K -10,000 Closed
CF
63
Centaurus Financial
California
– -$24K -2,000 Closed
SO
64
STRS Ohio
Ohio
– -$19.1K -1,500 Closed
SWM
65
SeaCrest Wealth Management
New York
– -$4K -350 Closed
PCM
66
Prelude Capital Management
New York
– -$4K -300 Closed
TDC
67
Thompson Davis & Co
Virginia
– -$4K -300 Closed
PIA
68
Piedmont Investment Advisors
North Carolina
– -$1K -90 Closed
1 2
3

RCUS Hedge Fund Activity: Q3 2018 in Review

57 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2018, worth a combined $313M — up 14% from $274M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of RCUS and 4 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 27 added.

The largest buyer was JP Morgan Chase, adding an estimated $2.75M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.26M.

  • 57 institutional investors held Arcus Biosciences (RCUS) as of Q3 2018, down from 64 in Q2 2018.
  • Funds reported $313M of Arcus Biosciences stock for Q3 2018, up 14% quarter-over-quarter.
  • 4 funds opened new Arcus Biosciences positions in Q3 2018 and 11 closed out, a net change of -7 holders.
  • The largest Arcus Biosciences buyer in Q3 2018 was JP Morgan Chase, an estimated $2.75M added.
  • The largest Arcus Biosciences seller in Q3 2018 was T. Rowe Price Associates, an estimated $3.26M sold.

Based on aggregated 13F filings for Q3 2018.